Chinese English Germany Japanese

TargetMol Chemicals Inc.회사는 제품 목록을 제공합니다.

회사 명:TargetMol Chemicals Inc.
전화:-
이메일:marketing@targetmol.com
국적:China
URL: https://www.targetmol.cn/
총 제품 수:28091
265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281

제품 카탈로그

Sodium 2-oxopropanoate；Sodium pyruvate피루브 산, 나트륨 염113-24-6C3H5NaO3
Palivizumab；Synagis|||MEDI 493팔리비주맙188039-54-5
Astegolimab；RG 6149|||MSTT 1041A2173054-79-8
Efalizumab；Hu1124|||HU 1124에팔리주마붐214745-43-4
Bersanlimab；BI-5051987854-08-9
Burfiralimab；hzVSF-v132460809-80-5
Carotuximab；1268714-50-6
Vixarelimab；2243320-83-2
Belimumab；LymphoStat B벨리무맙356547-88-1
Tomaralimab；OPN-3051449294-76-1
Siltuximab；CNTO-328541502-14-1
Suptavumab；REGN22221629615-23-1
Felzartamab；TJ-202|||MOR-03087|||MOR-2022197112-39-1
Flanvotumab；20D7S|||IMC 20D7S1188277-05-5
Garadacimab；CSL3122162134-62-3
Garetosmab；2097125-54-5
Aducanumab；아두카누맙1384260-65-4
Itepekimab；REGN-3500|||SAR-4403402226742-52-3
Latozinemab；GSK-4527223|||AL-0012376132-27-1
Lecanemab；BAN-24011260393-98-3
Leronlimab；674782-26-4
Spartalizumab；PDR0011935694-88-4
Nadecnemab；REGN-50692377679-19-9
Theralizumab；906068-56-2
Sibrotuzumab；BIBH 1|||Anti-Human FAP Recombinant Antibody216669-97-5
Ulocuplumab；BMS 936564|||MDX 13381375830-34-4
Xentuzumab；BI 8368451417158-65-6
Patritumab；1262787-83-6
GSNKGAIIGLM(131602-53-4(free base))；Amyloid beta-peptide(25-35)131602-53-4C45H81N13O14S
FG-3019；946415-13-0
Ganitumab；AMG 479905703-97-1
Lexatumumab；ETR2-ST01|||DR5 mAB|||HGS-ETR 2렉사투무맙845816-02-6
Sonepcizumab；LT 10091031360-18-5
Teneliximab；Chi220|||Anti-Human CD40 Recombinant Antibody|||BMS 224819299423-37-3
Nimacimab；JNJ 2463|||RYI-0182098636-09-8
Nirsevimab；1989556-22-0
Plozalizumab；1610761-46-0
Praluzatamab；2145109-70-0
Osocimab；BAY 12137902056878-75-0
Otilimab；GSK 3196165|||MOR1031638332-55-4
Belantamab；GSK28579142061894-48-0
Clesrovimab；MK-16542429913-18-6
Tafasitamab；MOR00208|||XmAb5574|||Tafasitamab-cxix1422527-84-1
Ragifilimab；INCAGN-01876|||INCAGN-1876|||CM-7012207590-51-8
Cobolimab；2022215-65-0
UK 088800；139756-21-1C17H20N4O2
Tesidolumab；LFG3161531594-08-7
Abciximab；C7E3압식시맙143653-53-6
Andecaliximab；GS-57451518996-49-0
Anetumab；1954758-84-9
Ascrinvacumab；PF-034469621463459-96-2
Ramiprilat；라미프리랏87269-97-4C21H28N2O5
Cinpanemab；BIIB0542094516-02-4
Elezanumab；AE12-1Y-QL|||ABT-5551791416-49-3
Enapotamab；1912423-61-0
Icrucumab；LY 3012212|||IMC-18F11024603-92-6
Ravulizumab；ALXN12101803171-55-2
Narsoplimab；OMS 7212108782-45-0
Nidanilimab；2171061-85-9
Erenumab；AMG-3341582205-90-0
Vofatamab；RG-7444|||B-701|||MFGR-1877S1312305-12-6
Talquetamab；JNJ-64407564|||JNJ-75642226212-40-2
Talacotuzumab；CSL 362|||JNJ 560224731826831-79-1
Spesolimab；BI 6551302097104-58-8
Donanemab；1931944-80-7
Quetmolimab；E-6011|||KANAb 0012084037-83-0
Petosemtamab；MCLA 1582213450-26-9
Oxelumab；Ro 49-89991|||R 4930|||huMAb OX 40L1186098-83-8
Ordesekimab；AMG 714|||PRV-015879293-15-9
Abrezekimab；UCB4144|||VR 9422043952-59-4
Siplizumab；MEDI-507288392-69-8
Clivatuzumab；1622075-09-5
D-Ribose 5-phosphate disodium dihydrate；207671-46-3C5H9Na2O8P2H2O
Mannan；만난9036-88-8
ACEPROMAZINE MALEATE；3598-37-6C23H26N2O5S
DSPE-NHS；1383932-86-2C49H89N2O13P
TV 3279；209394-29-6C16H20N2O2
(Iso)-BMT-124110 Formate；(R)-N-(8-((2-amino-2,4-dimethylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)acetamide Formate（1679370-98-9 Free base）
HDAC-IN-57；2716217-79-5C21H19N3O4
PLH1215；1332084-64-6
PLH2058；2525206-41-9
BRD4-IN-4；304685-40-3C17H18N2O3S
AB21 HCl；
icFSP1；1115910-36-5
2-aminobenzo[d]thiazol-6-ol；2-아미노-벤조티아졸-6-OL26278-79-5C7H6N2OS
2-Amino-6-bromopyridine；19798-81-3C5H5BrN2
Butylboronicacid；4426-47-5C4H11BO2
CCR1/5/8 activator 1；7-메틸린돌-3-카르복스알데하이드4771-50-0C10H9NO
5-Nitro-1,10-phenanthroline；5-NP4199-88-6C12H7N3O2
tert-Butyl5-bromo-1H-indole-1-carboxylate；N-Boc-5-bromoindoleTERT-BUTYL5-브로모인돌-1-카복실레이트182344-70-3C13H14BrNO2
ACHE Inhibitor 12；1H-인덴-1-온,2,3-디하이드로-2,6-디메틸-66309-83-9C11H12O
MyD88-IN-1；2911609-80-6C23H24N6O7S
Tezepelumab；Tezepelumab-ekko|||MEDI 19929|||AMG 157테제펠루맙1572943-04-4
Vorsetuzumab；SGN-701165740-62-4
Sibeprenlimab；2382896-07-1
Urelumab；BMS-663513|||BMS-66513934823-49-1
Telazorlimab；ISB-830|||GBR-8302126777-87-3
Ianalumab；VAY-7361929549-92-7
Tisotumab；1E10|||1.00E+101418628-81-5
Concizumab；mAb 2021|||NN 74151312299-39-0
265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281
Copyright 2019 © ChemicalBook. All rights reserved